Background and Purpose-Flow Diverters (FD) are a new emerging therapy for intracranial aneurysms. Initial reports focused on the treatment of proximally located aneurysms. We report our experience with FDs in the treatment of aneurysms at and beyond the circle of Willis. 
B
alloon and stent-assisted techniques have widened the indications of endovascular treatment of aneurysms that were otherwise considered unsuitable for coiling. [1] [2] [3] However, the treatment, either endovascular or surgical, of blisterlike and fusiform aneurysms remains challenging. A new generation of embolic devices, the flow diverters (FD), has recently been designed and developed to overcome the problem of these aneurysms. These FDs have the property of forming high-coverage mesh on the neck of the aneurysm to reduce the blood flow into the sac, and subsequently to induce the aneurysm thrombosis, all while preserving the patency of adjacent small vessels. 4 To date, few studies have been reported about the clinical experience of the pipeline embolization device (PED) with rather positive results. [5] [6] [7] The silk embolization device (SED) was approved in 2007 in Europe and few studies have been published so far. 8, 9 The authors showed a high rate of complications, and thus advocated both for the use of FDs only in otherwise untreatable aneurysms and for the need for longer follow-up. Distally located aneurysms can be difficult to treat with endovascular techniques that spare the parent artery, the reason being that parent artery occlusion is often an alternative treatment with potential risk of ischemia in the parent vessel territory. 10 -12 Up to now, reported series of aneurysms treated with FDs focused largely on lesions located upstream to the circle of Willis, mainly carotid siphon aneurysms. The aim of our study was to report our experience in the treatment of aneurysms at and beyond the circle of Willis with FDs.
Methods

Patient Selection
From September 2008 to May 2011, the clinical and angiographic outcomes of patients treated at our institution with FDs for aneurysms located at and beyond the circle of Willis were prospectively collected. Therapeutic alternatives were discussed between neurosurgical and neurointerventional teams in a multidisciplinary, decision-making process.
Endovascular Procedures
Anticoagulation with heparin was aimed at keeping the activated clotting time at 2 to 3 times above the normal value during catheterization and FD placement. In addition, in all patients with no history of subarachnoid hemorrhage (SAH) within the previous 4 weeks, 250 mg of aspirin was given intravenously. All patients harboring unruptured aneurysms were given dual antiplatelet therapy preoperatively that was continued for 6 months (clopidogrel, 75-150 mg; aspirin, 250 mg daily). In the setting of SAH, an intravenous (IV) bolus of 0.25 mg/kg of abciximab (Reopro, Lilly) was per-formed during the FD deployment and a continuous IV perfusion of 0.125 g/kg per minute for 12 hours was instaured immediately after the procedure. Clopidogrel and aspirin were then initiated 1 day after the procedure. Coiling was performed at the operator's discretion. In the patients treated with FDs and coils, the jailed microcatheter technique was used. A system of telescopic catheters was used to achieve a support for FD navigation: a long stiff introducer, 6 French (Destination, Terumo, or Strada, St Jude Medical), was placed within the cervical portion of parent artery, and a 6 French Fargo catheter (Balt) was then placed within the introducer to reach the cavernous internal carotid artery or the V3 segment of the vertebral artery based on targeted aneurysm location (anterior versus posterior circulation). Accurate measurement of the parent artery was performed on the 3D images acquired with rotational angiography with a dedicated workstation (XtraVision, Interventional Tools, Philips Healthcare) for vessel analysis before each procedure. Distal and proximal vessel diameters were taken into consideration as was neck width in the choice of the FD dimensions. Finally, the delivery catheter (Vasco 21, Balt for SED, and Marksman, EV3 for PED) was navigated on a 0.014-inch guide wire distal to the aneurysm neck on a straight portion of the parent vessel. Careful attention was paid not to position the distal tip of the delivery microwire of both SED and PED into small and angulated vessels to avoid arterial perforation or dissection. The FD was pushed through the microcatheter and was anchored for its first millimeters in a straight vessel portion. Then the partially deployed FD and the delivery microcatheter were slightly pulled back to be in the exact desired position and were deployed slightly while pushing on the FD. Angiographic images were acquired in anteroposterior, lateral, and working projections before and immediately after treatment.
Clinical Events
Any clinical events appearing in the postoperative course were noted. A neurological assessment was performed before the treatment, at discharge, and at follow-up.
Follow-Up
Angiographic images obtained immediately after endovascular treatment were compared with those obtained at each follow-up examination. Our standard angiographic follow-up protocol consisted of a first angiographic follow-up performed 3 to 6 months after endovascular treatment and a second angiographic follow-up performed 1 year after the first follow-up. In case of ruptured aneurysms, the first follow-up angiogram was anticipated.
Data Collection and Image Analysis
Patient age and sex, aneurysm location, type of aneurysm (saccular versus fusiform), presence of previous treatment, size, rupture status at presentation, degree of occlusion, intraflow-diverter stenosis, patency of merging artery whose origin was in the vicinity or was covered by the device, and clinical complications were noted. A single reader involved in the management and the patient treatment (with 15 years' experience in endovascular treatment of cerebral aneurysms) evaluated all the angiograms. Aneurysms occlusion was classified as total or not total. The patency of arterial branches was reported using the Thrombolysis in Myocardial Infarction (TIMI) scoring method. 13 variation between the proximal and distal part of the targeted vessel, we chose an FD adapted to the largest diameter. We did not use tapered FD. To increase the stability of the device, we chose an FD length at least 3 times the diameter of the parent vessel plus the neck size. Five aneurysms in 5 patients were treated with 2 FD because of suboptimal FD placement. A total of 32 FDs were deployed (25 SEDs, 7 PEDs). One single SED was used to treat 2 aneurysms in 3 patients (Table 1) .
Procedural Complications
In all but 1 case, FDs were successfully deployed. Conversely, the deployment of 2 SEDs in the distal middle cerebral artery (MCA) of a patient harboring a fusiform M4 aneurysm resulted in arterial perforation provoked by the distal wire of the SED. The endovascular procedure was immediately converted in PVO with coils. This technical complication remained clinically silent.
Clinical Complications
Transient (Յ1 day) or reversible (Յ7 days) ischemic complications were noted in 7.4% of the procedures (2/27). In 1 case, the patient sustained a reversible deficit of her left leg secondary to severe hypotension (blood loss in keeping with groin hematoma). In a second case, the patient had a transient hemiplegia of her left leg; this was caused by transitory flow reduction into the right A2 segment after SED deployment into right A1 and left A2 to treat a recurring aneurysm of the anterior communicating artery. Blood pressure increase was sufficient to restore the flow and revert clinical symptoms. Permanent neurological complication was deplored in 3.7% (1/27). In this case, a left large MCA aneurysm that had already recurred twice was treated for the third time with a PED and coils. The day after the procedure, the patient presented a sudden right hemiplegia and aphasia. An angiogram was immediately carried out showing a complete PED thrombosis. A balloon angioplasty was performed and the parent artery flow was restored. Despite that, the patient sustained a cerebral infarct with subsequent neurological deficit (Tables 1 and 2 , patient 4). The 30-day postprocedural mortality was 0.0%. There were no delayed neurological deficits.
Immediate Angiographic Outcome
Among the 30 aneurysms, 22 aneurysms were treated with PED or SED alone; among them, only 4 aneurysms (4/22; 18.2%) presented a total exclusion. Among the 7 aneurysms treated by FDs and coils, no one showed a complete angiographic exclusion.
Angiographic Follow-Up
Twenty-three of 30 aneurysms (76.7%) had been followed (2-26 months; mean, 13 months); 19 of the 22 aneurysms were treated by FD alone and 4 of the 7 aneurysms were treated by FDs with coils. In the group of aneurysms treated by FDs alone, there were 15/19 complete occlusions (78.9%).
In the group of aneurysms treated by FDs and coils, all 4 aneurysms improved to total occlusion. Among the 23 patients (24 less the PVO) who had been followed, we found 5 (21.7%) clinically silent intraflow-diverter stenoses. In these cases, we extended the period of antiplatelet therapy. Two of them, with a longer follow-up (18 months), showed improvement with total resolution of the stenosis. The arterial branch patency was assessed angiographically when the FD was deployed across the origin of a merging arterial branch (21/23 cases). A TIMI 3 flow was found in 8/21 cases (38.1%), a 
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Flow Diverters in the Setting of Subarachnoid Hemorrhage
Two aneurysms were treated with FDs in the setting of SAH. The first was a 1.2 mm aneurysm of the A1-A2 junction of the right anterior cerebral artery in a woman age 54 years who presented with a Fisher Grade 2 SAH. The aneurysm was treated with 2 SEDs. Immediate control angiogram showed persisting aneurysm circulation. A follow-up angiogram performed 2 weeks later attested the total circulatory exclusion of the lesion (Tables 1 and 2 , patient 10). The second was a 1.8 mm, blister-like dissecting aneurysm of the M1 segment of the left MCA in a man age 33 years with a Fisher Grade 2 SAH. Immediate control angiogram showed persisting aneurysm circulation. The follow-up angiogram at 2 months attested the total circulatory exclusion of the lesion (Tables 1  and 2 , patient 23).
Delayed Retraction of Embolic Device
In patient 1 (Tables 1 and 2 ), the distal end of a SED (used to treat a recurring MCA bifurcation aneurysm) was found retracted into the aneurysm sac at follow-up because of SED delayed shortening. The aneurysm was not excluded, and both branches of the MCA bifurcation remained patent.
Discussion
To date, clinical series dealing with FDs are scarce. [5] [6] [7] [8] [9] Only 2 series reported the use of FDs at and beyond the circle of Willis in a limited number of cases (Byrne et al, 4 cases; Lubicz et al, 13 cases). 8, 9 Previously, PVO was the sole endovascular option to treat distal fusiform aneurysms. Even if PVO seems to be a safe and durable therapy, in most cases it is difficult to predict the clinical outcome before the vessel occlusion. 10 The use of FDs in distal vessels allows an effective aneurysm treatment while maintaining the parent vessel patency. Alternatively, we reported 1 case in which the selective treatment by FD failed secondary to distal vessel perforation. We deplored 3 ischemic complications (1 permanent, 2 reversible). The thromboembolic complications reported in previous series were often related to poor FD opening at deployment, leading to flow reduction and parent artery thrombosis. 8 We did not confront problems in the deployment of FDs in our series, maybe because the targeted vessels were less angulated than in more proximal locations of the anterior circulation (eg, carotid siphon). As in the series of Lubicz et al, we faced the problem of FD retraction. 9 Interestingly, in our case, as well as in the case of Lubicz et al, the FD retraction occurred in a delayed fashion with a SED. In our case (a recurring MCA aneurysm whose fundus was protected by previously implanted coils) this event was clinically silent whereas, in the previously reported case (carotid ophthalmic aneurysm), the FD retraction into the sac led to a lethal aneurysm bleeding. All our patients underwent a dual antiplatelet therapy during 3 months that was continued as a monotherapy for 3 more months. Dual antiaggregation is known to increase the risk of general hemorrhagic complications 15 ; in particular, the occurrence of cerebral bleeding appears in correlation with the level of platelet inhibition. 16 Fortunately, none of our patients sustained delayed cerebral hemorrhagic events. We encountered 5/23 cases (21.7%) of asymptomatic intraflow-diverter stenosis at follow-up, a rate lower than that reported by Lubicz et al (33%) in a more heterogeneous population of aneurysms that included carotid siphon aneurysms with larger vessel diameters. 9 Interestingly, in light of our results, it seems that intraflow-diverter stenosis is not correlated with vessel caliber. Moreover, we reported 2 cases, those with longer follow-up, which showed resolution of the stenosis after prolonged antiplatelet therapy. Longer follow-up is still mandatory to understand the real behavior of these stenoses, which, in our limited experience, seem to be reversible. Concerning the effect on lateral branches, interestingly, in all cases of flow compromise (TIMI 0 -2 flows), none of the affected patients sustained neurological deficits; the collateral supply to the affected territories developed in the time interval of the procedure and in the follow-up angiogram probably slowly, and at the same time of the parent vessel flow reduction. Two aneurysms of our series were ruptured even though the requirement for dual antiplatelet medication represents a contraindication for the application of FD in the setting of SAH. In addition, because the FD does not elicit complete aneurysm occlusion at the time of placement, it may not provide the immediate protection from rebleeding offered by coiling or surgical clipping. However, surgical or conventional endovascular treatment of blister-like and very small aneurysms remains challenging. In this context, FDs that provide redirection of blood flow and aneurysm thrombosis, without taking the risk of aneurysm sac perforation by catheterization, might be an alternative and a simpler therapeutic option. 17
Conclusions
Our limited series carries the inherent restrictions of a small retrospective study, and larger series with longer follow-up are mandatory to draw definitive conclusions. However, it appeared that the treatment of distal aneurysms with FDs is feasible with a low rate of complications.
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